17 Aug Valproate containing medicines – High risk of congenital abnormalities and development disorders
Posted at 13:07h
in
Aspen Pharmacare, Brimpharm SA (Pty) Ltd, Adcock Ingram Limited, Sandoz SA (Pty) Ltd and Takeda (Pty) Ltd in collaboration with the South African Health Products Regulatory Authority (SAHPRA) would like to inform you of the risks related to the use of valproate containing medicines (sodium valproate, valproic acid) during pregnancy and lactation.
2019 Apr
Download latest version
Document Number:
DHCPL
Version:
1
Date Updated:
03/04/2019
File Type:
pdf
Category:
Communication To Health Care Professionals